Search the Newsreel

Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker

Balyasny Asset Management and its related entities have disclosed a beneficial ownership of approximately 4.99% in Camp4 Therapeutics Corp. (CAMP). This stake, totaling 2,591,097 shares, includes common stock and shares issuable upon warrant exercise, which are subject to a 4.99% Beneficial Ownership Limitation to …

Atria Investments Inc Acquires New Position in The Campbell's Company $CPB

Atria Investments Inc. has acquired a new stake in The Campbell's Company (NASDAQ:CPB), purchasing 50,994 shares valued at approximately $1,136,000 during the second quarter. This move is part of broader institutional investor activity, with several other firms also adjusting their positions in Campbell's. The …

Davide Campari-Milano N.V.: prezzo obiettivo e consensus degli analisti| CPR | NL0015435975| MarketScreener Italia

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) reported a Q2 loss of $0.22 per share, outperforming the Zacks Consensus Estimate of a $0.24 loss. The company's revenues for the quarter ended June 2026 reached $1.78 million, surpassing estimates by 31.78%. Despite beating earnings and revenue expectations, CAMP …

CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates

CAMP4 Therapeutics reported a Q2 net loss of $33.5 million, significantly wider than the previous year, primarily due to a $20.9 million non-cash derivative loss, causing EPS of $(0.58) to miss estimates. Despite missing revenue consensus, the company's revenue rose 18.8% year-over-year. Post-quarter, CAMP4 …

U.S. Retail Stocks Worth Watching As Cooling Inflation Eases Pressure On Big Ticket Spending

This article examines three U.S. consumer discretionary and retail stocks—MarineMax (HZO), Winnebago Industries (WGO), and Camping World Holdings (CWH)—that could benefit from cooling inflation and a less aggressive Federal Reserve. These companies, operating in sectors dependent on big-ticket spending, are navigating shifting economic conditions, …

CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028

CAMP4 Therapeutics reported a wider net loss of $33.5 million in Q2 2026, primarily due to a non-cash loss from a derivative liability. Despite this, the company's research and collaboration revenue increased, and it successfully extended its cash runway through the end of 2028 …

CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges

CAMP4 Therapeutics reported a widened net loss of $51.86 million for the six months ended June 30, 2026, primarily due to a $27.12 million non-cash charge from the remeasurement of a derivative tranche liability. Despite the loss, the company extended its cash runway through …

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics announced its Q2 2026 financial results and corporate highlights, including securing regulatory clearance in Australia and Argentina for its Phase 1/2 clinical trial of CMP-002 for SYNGAP-1 related disorder, with trial initiation expected in Q4 2026. The company also raised an additional …

The Campbell’s Company to Report Fourth Quarter and Full Year Fiscal 2026 Results on September 3, 2026

CAMDEN, N.J., August 13, 2026--(BUSINESS WIRE)--The Campbell's Company (NASDAQ:CPB) (Campbell's) announced it will report its financial results on September 3, 2026 for the fourth quarter and full year fiscal 2026 ended August 2, 2026. A press release, slide presentation, transcript and audio of pre-recorded …

Campbell’s Sets Sept. 3 Live Q&A on Fiscal 2026 Results

The Campbell's Company (NASDAQ: CPB) announced it will report its financial results for the fourth quarter and full fiscal year 2026 on September 3, 2026. A press release, slide presentation, transcript, and pre-recorded management remarks will be available at 7:15 a.m. ET, followed by …

Why Campbell's (CPB) Is Getting Attention Today

Campbell's (CPB) stock is attracting attention today after recent trading showed mixed short-term movements but weaker long-term performance. While a common narrative suggests the stock is 5.3% overvalued at $21.47 compared to its $22.60 close, another valuation method using its P/E ratio indicates it …

The Campbell's Company (NASDAQ:CPB) Given Consensus Recommendation of "Reduce" by Analysts

The Campbell's Company (NASDAQ:CPB) has received a consensus "Reduce" rating from 19 brokerages, with an average 12-month price target of $21.20, below its current share price of $22.60. The company recently reported quarterly EPS of $0.50, exceeding estimates, but revenue declined by 4.4% year-over-year. …

Campbell's (CPB) Stock May Be Cheap As Earnings Drive Value

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Campbell's stock has fallen sharply over the past few years, yet its current valuation checks suggest the market may now be pricing it …

Is Campbell's (CPB) Fully Priced After Its Recent Rebound?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recent share performance and business snapshot Campbell's (CPB) stock has drawn attention after a period of mixed returns, including declines over the past year alongside a gain …

Campbell's Co (CPB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Goldfish Are Going Gluten-Free

Campbell's will launch its first certified gluten-free Goldfish crackers nationwide in November, made with a gluten-free flour blend and real cheese. The new product responds to years of consumer requests and aims to boost the company's struggling snacks division. A 5-ounce bag will be …

Campbell’s Co. formulates gluten-free Goldfish

The Campbell's Co. is launching a gluten-free version of its popular Goldfish crackers, addressing consumer demand for inclusive snack options. Available in the classic cheddar flavor, Goldfish Gluten Free crackers will hit retailers nationwide in November. This move ensures that more families can enjoy …

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have given CAMP4 Therapeutics Corporation (NASDAQ:CAMP) an average recommendation of "Moderate Buy," with seven analysts recommending a buy and two a sell. The average 12-month price target is $8.36, significantly higher than the current share price of $4.22. Recent actions include an upgrade …

Campus Activewear profit rises 17.7% in Q1FY27 on volume surge

Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares

Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, and Ortav Yehudai have reported a beneficial ownership of 3,790,636 shares of Camp4 Therapeutics Corp (CAMP) common stock, representing 6% of the outstanding shares as of August 3, 2026. Trails Edge Biotechnology directly holds these …

Fluent Financial LLC Buys New Shares in The Campbell's Company $CPB

Fluent Financial LLC has acquired 62,577 new shares of The Campbell's Company (CPB) in the second quarter, valued at approximately $1.39 million. Despite this, analyst sentiment remains cautious with a consensus "Reduce" rating and an average price target of $21.20. Campbell's recently reported quarterly …

Projeções de Resultados: Campbell's Co (CPB) — LPA e Crescimento de Receita

Results: Campus Activewear Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Camplify (ASX:CHL) Cuts Its Loss by 62% and Swings Cash Flow Positive: Has the RV Turnaround Finally Arrived?

Camping World (CWH) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and President - Matthew WagnerChief Financial Officer - Tom KirnChief Administrative and Legal Officer - Lindsey ChristenSenior Vice President, Investor Relations - Brett Andress TAKEAWAYS …

Campus Activewear Share Price Today, Campus Activewear Stock Price Live NSE/BSE Updates

From Godrej Agrovet To Campus: Check Motilal Oswal's Latest Ratings, Target Prices After Q1 Results

Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

Richard Young, a director at CAMP4 Therapeutics (NASDAQ:CAMP), recently purchased 16,378 shares at $1.65 each, increasing his total holdings by 9.63% to 186,388 shares. Despite this insider buying, the stock fell 3.6% to $4.01 after the company reported a larger-than-expected quarterly loss of $0.32 …

Earnings call transcript: Campus Activewear Q1 2027 growth lifts outlook, shares slip

Campus Activewear Reports Double-Digit Revenue Growth in Q1 FY27

Campus Activewear releases Q1FY27 earnings call audio recording

Campus Activewear standalone net profit rises 17.75% in the June 2026 quarter